Liver Diseases  >>  ribavirin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

46 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ribavirin / Generic mfg.
NCT01910636: Efficacy and Safety of Sofosbuvir Plus Ribavirin in Japanese Adults With Chronic Genotype 2 HCV Infection

Checkmark
Sep 2014 - Sep 2014: 
Checkmark
Apr 2014 - Apr 2014: 
Completed
3b
153
Japan
Sofosbuvir, GS-7977, PSI-7977, Sovaldi®, RBV, Copegus®
Gilead Sciences
Hepatitis C
03/14
06/14
NCT01896193: Safety and Efficacy Study of Sofosbuvir Plus Ribavirin in Treatment-Naive Adults With Genotype 1 and 3 Chronic HCV Infection

Completed
3b
127
RoW
SOF, Sovaldi®, PSI-7977, GS-7977, RBV
Gilead Sciences
Hepatitis C
04/14
06/14
NCT00001729: Combination Drug Therapy for Patients With Hepatitis C

Completed
3
120
US
Ribavirin
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C, Fibrosis, Hemolytic Anemia
 
09/02
NCT00144469: A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Patients With Chronic Hepatitis C

Completed
3
300
Japan
peginterferon alfa-2a, rivavirin
Chugai Pharmaceutical
Chronic Hepatitis C
 
03/05
NCT00308048: 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

Completed
3
435
Europe
Pegylated Interferon alfa 2b and ribavirin
Ullevaal University Hospital, Schering-Plough
Hepatitis C Virus Infection
 
09/06
CIPPAD, NCT00136318: Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

Completed
3
208
Europe
Escitalopram, Placebo, Peginterferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin
Charite University, Berlin, Germany
Depression
09/08
09/08
NCT00304551: A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)

Completed
3
180
Japan
peginterferon alfa-2a 180μg, peginterferon alfa-2a 90μg, ribavirin
Chugai Pharmaceutical
Liver Cirrhosis, Chronic Hepatitis C
12/09
06/10
NCT01137383: Pegaferon and Ribavirin for Hepatitis C

Completed
3
108
RoW
Pegaferon (pegylated interferon alpha 2a) + ribavirin, Pegaferon
Tehran University of Medical Sciences, Pars No Tarkib Co
Hepatitis C
12/09
02/10
NCT00483938: The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)

Completed
3
236
US, Canada
Pegylated-interferon Alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
05/10
05/10
NCT00687219: Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116)

Completed
3
102
NA
Peginterferon alfa-2b, SCH 054031, Ribavirin, SCH 018908
Merck Sharp & Dohme LLC
Hepatitis C, Chronic, Liver Cirrhosis
10/10
10/10
NCT00516321 / 2006-004946-17: Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Subjects With Hepatitis C Related Liver Disease

Completed
3
687
US, Canada, Europe, RoW
eltrombopag, placebo
GlaxoSmithKline
Hepatitis C, Chronic
04/11
05/11
NCT00529568 / 2007-000292-42: Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Completed
3
759
US, Canada, Europe, RoW
eltrombopag, placebo
GlaxoSmithKline
Hepatitis C, Chronic
08/11
08/11
NCT01853254: A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials

Completed
3
272
US, Europe, RoW
Peginterferon alfa-2a, Pegasys, Ribavirin, Copegus
Hoffmann-La Roche
Hepatitis C, Chronic
09/11
09/11
NCT00800735 / 2008-002022-10: A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Completed
3
30
US, Canada, Europe
Pegylated-interferon alfa-2a, PEG-IFN alfa-2a, Pegasys, Ribavirin, Copegus, Ro 20-9963
Hoffmann-La Roche
Hepatitis C, Chronic
03/12
03/12
NCT00623428 / 2007-004993-15: A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral Response

Completed
3
235
US, Canada, Europe, RoW
peginterferon alfa-2a, Pegasys®, PEG-IFN alfa-2a, Ribavirin, Copegus®
Hoffmann-La Roche
Hepatitis C, Chronic
05/12
05/12
NCT01542788: Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION, VALENCE and NEUTRINO
Mar 2014 - Mar 2014: EASL 2014: FISSION, POSITRON, FUSION, VALENCE and NEUTRINO
Checkmark EASL 2014: FISSION, POSITRON, FUSION and NEUTRINO
More
Completed
3
278
US, Canada, RoW
SOF, Sovaldi®, GS-7977, PSI-7977, RBV, Placebo to match SOF, Placebo to match RBV
Gilead Sciences
Chronic Hepatitis C
11/12
02/13
NCT01604850: Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

Checkmark FUSION, NEUTRINO & VALENCE
Apr 2014 - Apr 2014: FUSION, NEUTRINO & VALENCE
Checkmark DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Apr 2014 - Apr 2014: DDW 2014: POSITRON, FISSION, FUSION & NEUTRINO
Checkmark DDW 2014: FUSION & NEUTRINO
More
Completed
3
202
US, Canada, RoW
SOF, Sovaldi®, GS-7977, PSI-7977, RBV, Placebo to match SOF, Placebo to match RBV
Gilead Sciences
Chronic Hepatitis C
02/13
05/13
NCT01318694 / 2010-022867-37: Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve Participants

Checkmark EASL 2013: FUNDAMENTAL
Apr 2013 - Apr 2013: EASL 2013: FUNDAMENTAL
Completed
3
1081
US, Canada, Europe, RoW
Alisporivir, DEB025, ALV, Peginterferon alfa-2a, Pegasys®, PEG, Ribavirin, Copegus®, RBV, ALV Placebo, Placebo
Debiopharm International SA
Hepatitis C
08/13
08/13
Hallmark QUAD, NCT01573351 / 2011-005422-21: Phase III ASV+DCV+Peg+Rib (Nulls/Partials)

Completed
3
398
US, Canada, Europe, RoW
Asunaprevir, BMS-650032, Daclatasvir, BMS-790052, Peg-interferon Alfa-2a, Pegasys®, Ribavirin, Copegus®
Bristol-Myers Squibb
Hepatitis C Virus
09/13
12/13
NCT01448044 / 2011-002793-23: Phase III BMS-790052 Add-On to Peg-Interferon Alfa-2a and Ribavirin in Naive Hepatitis C

Completed
3
152
US, Europe
BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Pegasys, Ribavirin, Copegus
Bristol-Myers Squibb
Hepatitis C
10/13
01/14
NCT01667731: Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Checkmark PHOTON-1
Jul 2014 - Jul 2014: PHOTON-1
Checkmark APASL 2014: PHOTON-1
Mar 2014 - Mar 2014: APASL 2014: PHOTON-1
Checkmark CROI 2014: PHOTON-1
More
Completed
3
224
US
SOF, GS-7977, PSI-7977, Sovaldi®, RBV
Gilead Sciences
Hepatitis C, Human Immunodeficiency Virus
11/13
02/14
ION-2, NCT01768286: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection

Checkmark Resistance 2014: ION-1, ION-2 & ION-3
Jun 2014 - Jun 2014: Resistance 2014: ION-1, ION-2 & ION-3
Checkmark EASL 2014: ION-2
Apr 2014 - Apr 2014: EASL 2014: ION-2
Checkmark DDW 2014: ION-2
More
Completed
3
441
US
LDV/SOF, Harvoni®, GS-5885/GS-7997, RBV
Gilead Sciences
Chronic Hepatitis C Virus
11/13
02/14
NCT01579474: Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Completed
3
131
Japan
BI 201335 high dose, BI 201335 low dose
Boehringer Ingelheim
Hepatitis C
12/13
12/13
NCT01718145: A Phase 3, Comparative Study of Asunaprevir and Daclatasvir Combination Therapy Versus Telaprevir Therapy in Japanese HCV Subjects

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Completed
3
258
Japan
Daclatasvir, Asunaprevir, Ribavirin, pegIFNα-2b, Telaprevir
Bristol-Myers Squibb
Hepatitis C Virus Infection
12/13
12/14
NCT01851330: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Checkmark AASLD 2014: ION-3
Oct 2014 - Oct 2014: AASLD 2014: ION-3
Checkmark Resistance 2014: ION-1, ION-2 & ION-3
Jun 2014 - Jun 2014: Resistance 2014: ION-1, ION-2 & ION-3
Checkmark ION-3
More
Completed
3
647
US
LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV
Gilead Sciences
Chronic Hepatitis C Virus
12/13
03/14
NCT01728324 / 2012-003535-27: Phase 3 Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Treatment of Patients With Hepatitis C Infection, Including Patients Who Are Not Eligible to Receive Peginterferon: HCVerso2

Checkmark AASLD 2014: HCVerso 2
Oct 2014 - Oct 2014: AASLD 2014: HCVerso 2
Completed
3
496
US, Canada, Europe, RoW
BI 207127-placebo: 8-week treatment, Ribavirin: 24-week treatment, BI 207127: 24-week treatment, Faldaprevir: 24-week treatment, Ribavirin-placebo: 8-week treatment, Faldaprevir-placebo: 8-week treatment, Faldaprevir: 16-week treatment, Ribavirin: 16-week treatment, RBV: 24-week treatment, BI 207127: 16-week treatment
Boehringer Ingelheim
Hepatitis C, Chronic
02/14
01/15
NCT01701401 / 2012-003387-43: Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV

Checkmark ILC 2016 (ION-1 Study)
Mar 2016 - Mar 2016: ILC 2016 (ION-1 Study)
Checkmark Resistance 2014: ION-1, ION-2 & ION-3
Jun 2014 - Jun 2014: Resistance 2014: ION-1, ION-2 & ION-3
Checkmark EASL 2014: ION-1
More
Completed
3
870
US, Europe
LDV/SOF, Harvoni®, GS-5885/GS-7977, RBV
Gilead Sciences
Chronic Hepatitis C Virus
03/14
04/14
NCT01783678 / 2012-004154-28: A Phase 3, Open-label Study to Investigate the Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2, 3 and 4 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults

Completed
3
275
Europe, RoW
Sofosbuvir, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Chronic Hepatitis C, Human Immunodeficiency Virus
04/14
07/14
NCT01838590: Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Checkmark AASLD 2014
Oct 2014 - Oct 2014: AASLD 2014
Completed
3
103
RoW
SOF, Sovaldi®, GS-7977, RBV
Gilead Sciences
Hepatitis C Virus
05/14
08/14
NCT00239252: Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

Completed
3
Japan
Interferon alfacon-1
Astellas Pharma Inc, Schering-Plough
Hepatitis C
 
 
RibaC, NCT01226771 / 2010-018332-41: Ribavirin Loading Dose or Priming and Concentration Targeting for HCV Genotype 1

Completed
3
105
Europe
Ribavirin "loading" dose given, "Priming" dose of ribavirin given, Group C ("Standard-of-Care")
Göteborg University, The Swedish Research Council, Roche Pharma AG
Hepatitis C
09/14
09/14
NCT01753557: Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C

Completed
3
54
Japan
MP-424, RBV, PEG-IFN alfa-2a
Mitsubishi Tanabe Pharma Corporation
Chronic Hepatitis C (CHC)
11/14
11/14
ALLY 1, NCT02032875: Phase III Daclatasvir, Sofosbuvir, and Ribavirin in Cirrhotic Participants and Participants Post-liver Transplant

Checkmark DDW 2016 (ALLY-1 study)
Apr 2016 - Apr 2016: DDW 2016 (ALLY-1 study)
Checkmark P3 data of ALLY-1 study
Sep 2015 - Sep 2015: P3 data of ALLY-1 study
Completed
3
116
US
Daclatasvir, BMS-790052, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Hepatitis C
11/14
01/16
NCT01903278: Efficacy and Safety Study of PEG-IFN-SA and Ribavirin to Treat Chronic Hepatitis C

Completed
3
719
RoW
PEG-IFN-SA /RBV, Pegasys /RBV
Beijing Kawin Technology Share-Holding Co., Ltd.
Chronic Hepatitis c
08/15
08/15
NCT02103439: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Completed
3
140
RoW
Algeron, Cepeginterferon alfa-2b, PegIntron, peginterferon alfa-2b
Biocad
Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection
08/15
08/15
DIMENSION, NCT01866930 / 2012-003280-22: Efficacy and Safety Study of Pegylated Interferon Lambda-1a With Ribavirin and Daclatasvir, to Treat naïve Subjects With Chronic HCV Genotypes 1, 2, 3, and 4 Who Are Co-infected With HIV

Terminated
3
453
Europe, Canada, US, RoW
Pegylated Interferon Lambda-1a, BMS-914143, Daclatasvir (DCV), BMS-790052, Ribasphere (RBV)
Bristol-Myers Squibb
Chronic Hepatitis C Infection
08/15
08/15
ASTRAL-3, NCT02201953 / 2014-001682-27: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection

Checkmark ASTRAL-1, 2, 3 & 4 studies
Sep 2015 - Sep 2015: ASTRAL-1, 2, 3 & 4 studies
Completed
3
558
Canada, US, Europe, RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV
Gilead Sciences
Hepatitis C Virus Infection
09/15
12/15
NCT01753570: Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Naïve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)

Completed
3
74
Japan
MP-424, RBV(24 weeks), IFN beta(24 weeks), RBV(48 weeks), IFN beta(48 weeks)
Mitsubishi Tanabe Pharma Corporation, Toray Industries, Inc
Chronic Hepatitis C(CHC)
10/15
10/15
NCT02319031 / 2014-005310-28: Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis

Checkmark DDW 2016 (ALLY-3 & ALLY-3+)
Apr 2016 - Apr 2016: DDW 2016 (ALLY-3 & ALLY-3+)
Completed
3
53
Europe, RoW
Daclatasvir, Sofosbuvir, Ribavirin
Bristol-Myers Squibb
Hepatitis C
10/15
12/15
Turquoise-IV, NCT02216422: A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection

Completed
3
36
US, RoW
Ombitasvir/Paritaprevir/Ritonavir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, Ritonavir also known as norvir, Dasabuvir, ABT-333, Ribavirin (RBV)
AbbVie
Chronic Hepatitis C Virus (HCV) Infection
12/15
12/15
NCT01889433: An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Completed
3
170
RoW
Algeron, Cepeginterferon alfa-2b, Pegasys, Peginterferon alfa-2a
Biocad
Hepatitis, Hepatitis C
12/15
12/15
TURQUOISE-CPB, NCT02219477 / 2014-001477-13: A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis

Completed
3
36
US, Canada, Europe
ombitasvir/paritaprevir/ritonavir, ABT-267 also known as ombitasvir, ABT-450 also known as paritaprevir, ritonavir also known as norvir, dasabuvir, ABT-333, ribavirin
AbbVie
Chronic Hepatitis C, Decompensated Cirrhosis, Hepatitis C Virus
06/16
03/17
AGATE-1, NCT02265237 / 2014-001496-31: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis

Checkmark DDW 2016 (AGATE-I)
Apr 2016 - Apr 2016: DDW 2016 (AGATE-I)
Completed
3
184
NA
ombitasvir/paritaprevir/ritonavir, norvir (ritonavir), paritaprevir (ABT-450), ombitasvir (ABT-267), ribavirin
AbbVie
Hepatitis C Virus
07/16
04/17
NCT02207088: Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease

Completed
3
68
NA
ombitasvir/paritaprevir/ritonavir, ABT-450/r/ABT-267, Viekira Pak, paritaprevir also known as ABT-450, ombitasvir also known as ABT-267, dasabuvir also known as ABT-333, dasabuvir, ABT-333, Ribavirin, RBV
AbbVie
Chronic Hepatitis C, Hepatitis C Virus, Compensated Cirrhosis, Severe Renal Impairment, End-stage Renal Disease
12/16
12/16
SCIN-C, NCT00624325: Subcutaneous Continuous Infusion of Interferon Alfa-2b and Ribavirin in Hepatitis C Genotype 1 Nonresponders

Completed
2/3
30
Europe
interferon alfa-2b, Intron A
Foundation for Liver Research
Chronic Hepatitis C
06/10
12/10
No, NCT01006031 / 2009-009438-34: Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous nresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Completed
2/3
25
Europe
Pegylated interferon alfa-2a and Ribavirin, Pegasys, Copegus
Sociedad Andaluza de Enfermedades Infecciosas
Liver Cirrhosis, Hepatitis C Virus, HIV Infection
12/11
12/11

Download Options